BenevolentAI SPAC Presentation Deck

ABOUT Benevolent Founded in 2013. Offices in London, NYC and laboratories in REA Cambridge UK. Full molecular biology, medicinal chemistry and in vivo pharmacology capabilities for in house experimentation. 300 World-class scientists & technologists PIPELINE 20+ Platform Generated Disease Programmes ≈50% Advanced degrees Ph.D or M.D 40% Data Science, Software Engineering & Automation 35% Biology, Chemistry & Development ✓ Atopic Dermatitis asset in Phase I ✔ Novel target for UC asset in IND-enabling studies ✔ Novel target selected by AstraZeneca as part of successful collaboration in CKD ✔ Al-driven drug repurposing hypothesis led to FDA approval of Eli Lilly drug for COVID-19; 38% reduction in mortality 3 Scientifically-validated Al Platform and R&D engine from TargetID to clinical development Platform and Knowledge Graph leverage a wealth of peer-reviewed research and diverse biomedical data to build a broad spectrum of evidence defining complex disease biology 7 years investment in data curation, AI/NLP relationship extraction, models development result in generation of proprietary insights at significant scale. Data introspection tools deliver multi-factorial analysis and perform real-time in-silico experimentation to validate targets Industry-unique approach drives higher confidence decisions downstream and accelerates the development of de-risked novel drug candidates

View entire presentation